Community Guidelines

The @FightCancerNZ MSD New Zealand Twitter account is administered by MSD and a third-party service provider. Please note that we will respond to comments during business hours (9am-5pm, Monday to Friday). If you have an urgent enquiry regarding one of our medicines, please seek advice from a healthcare professional and follow the guidelines below.

We update and monitor this page keeping an eye out for anything that breaks the house rules or Twitter Terms of Service. The @FightCancerNZ MSD New Zealand Twitter account is not responsible for third party sites and makes no representation in relation to the accuracy, reliability, suitability, currency, completeness or lawful nature of such content.

We do not allow the use of the @FightCancerNZ MSD New Zealand Twitter account for any unauthorised third-party advertising or promotion, solicitation of donations or raising money, whether for a charity or otherwise.

 

House Rules

We welcome your contribution the @FightCancerNZ MSD New Zealand Twitter handle and we want to ensure that everyone understands the guidelines for participating. Your use is conditional upon you accepting and complying with these guidelines.

Some general considerations:

  • You need to be a registered member of Twitter and accept Twitter’s User Agreement to join the conversation
  • Please do not upload pictures of under 18s without consent or any other content that may be deemed irrelevant. Any content that MSD deems irrelevant (in its sole discretion) will be removed
  • Please don’t attempt to impersonate other people, well known or otherwise
  • Copyright, plagiarism and ownership – before you upload content please make sure you own the rights e.g. Images, video and music all need to be your own creation. If content is suspected not to be yours it will be removed.

MSD is part of a highly-regulated industry with unique legal considerations. We are governed by the Medicines New Zealand Code of Conduct and the Medicines Act, which means we cannot engage in conversations about our products, other companies’ products or treatment options in the public domain. If you would like to discuss one of our medicines with us; contact our medical information team: DPOC.Australia@merck.com

The information on the @FightCancerNZ MSD twitter handle is provided for your general information only and does not constitute medical advice and should not be interpreted as treatment recommendations. You should not use or act on this information without first seeking proper information and advice from your qualified health provider.

In our community, discussions need to be constructive and not breach local legislation. For this reason, comments may be deleted for:

  • Naming (including generic names) our products or other companies’ products
  • Offering health or medical advice
  • Profanity, defamatory, libelous, offensive, abusive, discriminatory or demeaning content, including images, videos or links
  • Threatening, condoning violence or illegal behavior
  • Publishing personal information e.g. names (note this does not include tagging of profiles) email addresses, phone numbers, personal photos or videos
  • Publishing propriety, confidential, sensitive or non-public information
  • Violating copyright or intellectual property laws
  • Publishing false, inaccurate or misleading information
  • Publishing information that is commercial in nature, with an intent to sell products or services or recruit followers to other social communities
  • Being excessively repetitive and/or disruptive
  • Violating Twitters Terms of Service
  • MSD may remove your comments or posts for legal, editorial or operational reasons. We reserve the right to delete any posts or comments at our sole discretion

Please be aware that those who violate the above rules may be blocked from the @FightCancerNZ MSD Twitter handle. In this case, the user would no longer be able to follow our news or comment on our posts.

Twitter accounts that MSD follows and content that MSD favorites or retweets is not an indication of MSD’s endorsement of these accounts or the content they produce. Nor is it an indication that we are engaged in a business relationship with the content authors.

 

Safety information (side effects and product complaints)

If you believe you have experienced a side effect or quality concern from an MSD product and need medical advice, please consult your doctor. Additionally, you can report this to the MSD Medical Department at DPOC.Australia@merck.com or call NZ 0800 500 673.

 

Using and storing personal identifying information

MSD will not collect, store, disclose or share personal identifying information (such as your Twitter profile, unique ID, email) on the @FightCancerNZ MSD Twitter handle; unless we have obtained proper consent.

However, in the case of reporting any safety information (e.g. a side effect or product issue) we will need to store and use personally identifying information, such as your initials, location, health-related information or similar; in accordance with local and international regulations and MSD procedures.

This information is required to be submitted to the MSD pharmacovigilance department and/or regulatory authorities. We are also required to store your personal identifying information for auditing purposes. Any personal information collected by MSD will be handled in accordance with MSD’s Privacy Policy.

Merck Sharp & Dohme (New Zealand) Limited (“MSD”) will collect, record and use your personal information for the purposes of adhering to local and international regulations and MSD procedures. If you choose not to provide us with your personal information, we may not be able to fulfill these purposes. We will keep your personal information for only as long as is necessary to carry out the purposes described above (unless we are required or permitted by law to hold the information for a longer period). We may disclose your personal information to organisations who assist us and our affiliated companies (which may be located in other countries including the United States, United Kingdom, Singapore, South America, Poland, China or India). If you would like to know more about our privacy policy, including how to access and seek correction of the personal information MSD holds about you, how to complain about a breach of the New Zealand Privacy Principles, and how MSD handles such complaints, please go to


https://www.msdprivacy.com/nz/en/index.html
or contact our Privacy Officer at:
C/O MSD, PO Box 99-851, Newmarket, Auckland 1149, T +64 9 523 6000,
E msd_privacy_office@msd.com.

Our third-party service provider helps us manage comments and messages received via the @FightCancerNZ MSD twitter handle; which means that they have access to any personal identifying information you share with us. Third-party service providers are contractually bound and trained to ensure they follow the process adopted for the protection and security of our personal identifying information.

Please note that Twitter also has access to information you share with us. For more details please refer to the Twitter Privacy Policy.

Thank you for reading and following @FightCancerNZ on Twitter.

NZ-KEY-00291 DA2039MW First issued February 2020.

NZ-KEY-00328

+

Important Safety Information

KEYTRUDA contains the active substance called pembrolizumab and is a medicine that may treat certain cancers by working with your immune system.

KEYTRUDA is available as a 50 mg powder for infusion and 100 mg/4 mL (25 mg/mL) concentrate for solution for infusion.

KEYTRUDA can only be used in children below 18 years of age with MSI-H or dMMR cancers. It is not known if KEYTRUDA is safe and effective in children with MSI-H or dMMR cancer of the brain or spinal cord (central nervous system cancers).

Tell your doctor if you have a disease of your immune system such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant or have had a bone marrow (stem cell) transplant that used donor stem cells (allogeneic); have pneumonia or swelling of your lungs (called pneumonitis); have liver problems; or have any other medical problems.

If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor. KEYTRUDA can harm your unborn baby. Effective contraception must be used during treatment with KEYTRUDA and for at least 4 months after the last dose of KEYTRUDA for woman who could become pregnant.

If you are breastfeeding, tell your doctor. Do not breastfeed while taking KEYTRUDA.

Tell your doctor if you are taking any other medicines, including medicines that can be bought without a prescription from a pharmacy, supermarket or health food shop, or other medicines that make the immune system weak. Examples of these may include steroids, such as prednisone.

KEYTRUDA is given through an IV for about 30 minutes. Most people get KEYTRUDA every 3 weeks or every 6 weeks, depending on age and the dose given. Your doctor will decide how many treatments you need. KEYTRUDA may be given in combination with other anti-cancer medicines.

What are the possible side effects of KEYTRUDA?

KEYTRUDA can have some serious side effects. These side effects can sometimes become life- threatening and can lead to death. These side effects may happen any time during treatment or even after treatment has ended. More than one side effect can be experienced at the same time.

Call or see your doctor right away if you develop any of the following symptoms:

Lung problems. Signs and symptoms of lung problems may include shortness of breath, chest pain, or coughing.

Intestinal problems. Signs and symptoms of problems with your intestines may include diarrhea or more bowel movements than usual, stools that are black, tarry, sticky, or have blood or mucus, or severe stomach pain or tenderness.

Liver problems. Signs and symptoms of liver problems may include nausea or vomiting, feeling less hungry, pain on the right side of your stomach, your skin looks yellow, the whites of your eyes look yellow, dark urine or you bleed or bruise more easily than normal.

Hormone gland problems (especially the thyroid, pituitary, adrenal glands). Signs and symptoms of hormone gland problems may include rapid heartbeat, weight loss or weight gain, increased sweating, hair loss, feeling cold, constipation, your voice gets deeper, muscle aches, dizziness or fainting, or headaches that will not go away or unusual headache.

Kidney problems. Signs and symptoms of kidney problems may include change in the amount or color of your urine.

Skin problems. Signs and symptoms of skin problems may include rash, itching, blisters, peeling or skin sores, or ulcers in mouth or in lining of nose, throat, or genital area.

Problems in other organs. Signs and symptoms of problems in other organs may include muscle pain or weakness, changes in eyesight, stomach area pain with nausea and vomiting (pancreatitis), shortness of breath, irregular heartbeat, feeling tired, or chest pain (myocarditis), confusion, fever, memory problems, or seizures (encephalitis), swollen lymph nodes, rash or tender lumps on skin, cough, or eye pain (sarcoidosis), or pain, numbness, tingling, or weakness in the arms or legs; bladder or bowel problems including needing to urinate more frequently, urinary incontinence, difficulty urinating and constipation (myelitis).

Infusion (IV) reactions. Signs and symptoms of infusion reactions may include shortness of breath, itching or rash, dizziness or fever.

Rejection of a transplanted organ. People who have had an organ transplant may have an increased risk of organ transplant rejection. Your doctor should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.

Graft-versus-host-disease (GVHD) in people with bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). GVHD may occur if you had this transplant in the past. Your doctor will monitor you for the following signs and symptoms: skin rash, liver inflammation, abdominal pain, and diarrhoea.

Common side effects:

Very common side effects (may affect more than 1 in 10 people) include: diarrhoea, nausea, itching, rash, joint pain, back pain, feeling tired, cough, patches of skin which have lost colour, stomach pain and decreased sodium levels in the blood.

Common side effects (reported in more than 1 in 5 people) when KEYTRUDA was given in combination with chemotherapy include: hair loss, feeling tired, diarrhoea, decrease in white blood cell count, joint pain and rash.

The most common side effects when KEYTRUDA is given in combination with axitinib are: diarrhoea, high blood pressure, fatigue, low levels of thyroid hormone, decreased appetite, blisters or rash on the palms of your hands or soles of your feet, nausea, increase in liver enzyme levels, hoarseness, cough and constipation.

The most common side effects when KEYTRUDA is given to children are: fever, vomiting, fatigue, constipation, stomach pain and nausea.

Less common side effects can happen. KEYTRUDA may cause other side effects that are not listed. If you have any side effect that bothers you or that does not go away, tell your doctor.

For more information, please talk to your doctor. The information on the website should be discussed with your healthcare professional and does not replace their advice.

KEYTRUDA has risks and benefits. Talk to your doctor to see if KEYTRUDA is right for you. KEYTRUDA is a funded medicine for patients with melanoma which cannot be removed by surgery alone or when it has spread – restrictions apply. KEYTRUDA is an unfunded medicine for the treatment of melanoma after surgery, and for patients with NSCLC, HNSCC, cHL, urothelial carcinoma, MSI-H/dMMR cancer and RCC. Ask your health professional about the cost of the medicine and any other medical fees that may apply. Use only as directed and if symptoms continue or you have side effects, see your doctor, pharmacist, or health professional.

Additional product information and the Consumer Medicine Information (CMI) can be obtained by phoning 0800 500 673 or is available via www.medsafe.govt.nz

Based on the CMI and Data Sheet prepared 1 June 2020.

Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland. NZ-KEY-00522 TAPS NA 12128 MSD9764 Updated: September 2020.

2015-2020


KEYTRUDA® (pembrolizumab) 50mg powder for infusion

KEYTRUDA® (pembrolizumab) 100 mg/4 mL (25 mg/mL) concentrate for solution for infusion

KEYTRUDA is a Prescription Only Medicine and is used:

  • in the treatment of melanoma which cannot be removed by surgery alone or when it has spread to multiple sites in the body
  • in treatment of melanoma after surgery to help prevent the cancer from coming back
  • in the treatment of a kind of lung cancer called non-small cell lung cancer (NSCLC)
  • in the treatment of classical Hodgkin Lymphoma (cHL)
  • in the treatment of urothelial carcinoma, including bladder cancer
  • in the treatment of a kind of head and neck cancer called head and neck squamous cell carcinoma (HNSCC)
  • in the treatment of a kind of cancer in adults and children that can occur in any part of the body and is shown by a laboratory test to be microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
  • in combination with axitinib for the treatment of a kind of cancer called renal cell carcinoma (RCC)

KEYTRUDA contains the active substance called pembrolizumab and is a medicine that may treat certain cancers by working with your immune system.

KEYTRUDA can only be used in children below 18 years of age with MSI-H or dMMR cancers. It is not known if KEYTRUDA is safe and effective in children with MSI-H or dMMR cancer of the brain or spinal cord (central nervous system cancers).

Tell your doctor if you have a disease of your immune system such as Crohn’s disease, ulcerative colitis, or lupus; have had an organ transplant or have had a bone marrow (stem cell) transplant that used donor stem cells (allogeneic); have pneumonia or swelling of your lungs (called pneumonitis); have liver problems; or have any other medical problems.

If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor. KEYTRUDA can harm your unborn baby. Effective contraception must be used during treatment with KEYTRUDA and for at least 4 months after the last dose of KEYTRUDA for woman who could become pregnant.

If you are breastfeeding, tell your doctor. Do not breastfeed while taking KEYTRUDA.

Tell your doctor if you are taking any other medicines, including medicines that can be bought without a prescription from a pharmacy, supermarket or health food shop, or other medicines that make the immune system weak. Examples of these may include steroids, such as prednisone.

KEYTRUDA is given through an IV for about 30 minutes. Most people get KEYTRUDA every 3 weeks or every 6 weeks, depending on age and the dose given. Your doctor will decide how many treatments you need. KEYTRUDA may be given in combination with other anti-cancer medicines.

What are the possible side effects of KEYTRUDA?

KEYTRUDA can have some serious side effects. These side effects can sometimes become life- threatening and can lead to death. These side effects may happen any time during treatment or even after treatment has ended. More than one side effect can be experienced at the same time.

Call or see your doctor right away if you develop any of the following symptoms:

Lung problems. Signs and symptoms of lung problems may include shortness of breath, chest pain, or coughing.

Intestinal problems. Signs and symptoms of problems with your intestines may include diarrhea or more bowel movements than usual, stools that are black, tarry, sticky, or have blood or mucus, or severe stomach pain or tenderness.

Liver problems. Signs and symptoms of liver problems may include nausea or vomiting, feeling less hungry, pain on the right side of your stomach, your skin looks yellow, the whites of your eyes look yellow, dark urine or you bleed or bruise more easily than normal.

Hormone gland problems (especially the thyroid, pituitary, adrenal glands). Signs and symptoms of hormone gland problems may include rapid heartbeat, weight loss or weight gain, increased sweating, hair loss, feeling cold, constipation, your voice gets deeper, muscle aches, dizziness or fainting, or headaches that will not go away or unusual headache.

Kidney problems. Signs and symptoms of kidney problems may include change in the amount or color of your urine.

Skin problems. Signs and symptoms of skin problems may include rash, itching, blisters, peeling or skin sores, or ulcers in mouth or in lining of nose, throat, or genital area.

Problems in other organs. Signs and symptoms of problems in other organs may include muscle pain or weakness, changes in eyesight, stomach area pain with nausea and vomiting (pancreatitis), shortness of breath, irregular heartbeat, feeling tired, or chest pain (myocarditis), confusion, fever, memory problems, or seizures (encephalitis), swollen lymph nodes, rash or tender lumps on skin, cough, or eye pain (sarcoidosis), or pain, numbness, tingling, or weakness in the arms or legs; bladder or bowel problems including needing to urinate more frequently, urinary incontinence, difficulty urinating and constipation (myelitis).

Infusion (IV) reactions. Signs and symptoms of infusion reactions may include shortness of breath, itching or rash, dizziness or fever.

Rejection of a transplanted organ. People who have had an organ transplant may have an increased risk of organ transplant rejection. Your doctor should tell you what signs and symptoms you should report and monitor you, depending on the type of organ transplant that you have had.

Graft-versus-host-disease (GVHD) in people with bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). GVHD may occur if you had this transplant in the past. Your doctor will monitor you for the following signs and symptoms: skin rash, liver inflammation, abdominal pain, and diarrhoea.

Common side effects:

Very common side effects (may affect more than 1 in 10 people) include: diarrhoea, nausea, itching, rash, joint pain, back pain, feeling tired, cough, patches of skin which have lost colour, stomach pain and decreased sodium levels in the blood.

Common side effects (reported in more than 1 in 5 people) when KEYTRUDA was given in combination with chemotherapy include: hair loss, feeling tired, diarrhoea, decrease in white blood cell count, joint pain and rash.

The most common side effects when KEYTRUDA is given in combination with axitinib are: diarrhoea, high blood pressure, fatigue, low levels of thyroid hormone, decreased appetite, blisters or rash on the palms of your hands or soles of your feet, nausea, increase in liver enzyme levels, hoarseness, cough and constipation.

The most common side effects when KEYTRUDA is given to children are: fever, vomiting, fatigue, constipation, stomach pain and nausea.

Less common side effects can happen. KEYTRUDA may cause other side effects that are not listed. If you have any side effect that bothers you or that does not go away, tell your doctor.

For more information, please talk to your doctor. The information on the website should be discussed with your healthcare professional and does not replace their advice.

KEYTRUDA has risks and benefits. Talk to your doctor to see if KEYTRUDA is right for you. KEYTRUDA is a funded medicine for patients with melanoma which cannot be removed by surgery alone or when it has spread – restrictions apply. KEYTRUDA is an unfunded medicine for the treatment of melanoma after surgery, and for patients with NSCLC, HNSCC, cHL, urothelial carcinoma, MSI-H/dMMR cancer and RCC. Ask your health professional about the cost of the medicine and any other medical fees that may apply. Use only as directed and if symptoms continue or you have side effects, see your doctor, pharmacist, or health professional.

Additional product information and the Consumer Medicine Information (CMI) can be obtained by phoning 0800 500 673 or is available via www.medsafe.govt.nz

Based on the CMI and Data Sheet prepared 1 June 2020.

Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland. NZ-KEY-00522 TAPS NA 12128 MSD9764 Updated: September 2020.

Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved.

2015-2020